MicroQuin, a biotechnology startup, used the International Space Station (ISS) National Laboratory to grow 3D breast and prostate cancer cell cultures to learn more about how these cancers develop and grow.
Via MicroQuin's ISS National Lab-sponsored research, its team identified microgravity-induced changes in cancer cells signaling, indicating that cancer cell survival depends on their ability...
Home-based cancer care platform Reimagine Care is expanding its partnership with Houston-based Memorial Hermann Health System beyond its flagship hospital, Memorial Hermann-Texas Medical Center, to offer oncology patients digital, virtual and in-home care.
Reimagine Care partners with providers and health plans to coordinate care in the home to avoid unnecessary inpatient visits. Reimagine...
GE HealthCare has partnered with radiation therapy company Elekta to develop new software to improve clinicians experience and enable greater precision treatment.
Elekta will use GE HealthCare’s MIM Software imaging management platform, which GE HealthCare acquired earlier this month. MIM’s auto contouring and treatment management platform will allow Elekta to develop radiation oncology...
Korean researchers develop biosensor to measure serotonin levels in real-time
A research team from the Korea Research Institute of Bioscience and Biotechnology has developed a biosensor that can track serotonin levels in real time for the diagnosis of depression.
Depression, which affects over a million South Koreans, is believed to be partly caused by imbalances in the level of neurotransmitters...
Oxford-based biotech company, Theolytics has announced the closing of a US $6.8 million (£5 million) Series A round.
The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI).
The financing will be used to progress the company’s pipeline of candidates towards human clinical trials.
WHY IT MATTERS
Theolytics will...
Driver, the pricey mobile app designed to link cancer patients to appropriate treatment or relevant clinical trials, appears to have bitten off a bit more than it could chew. This morning STAT reported that the service, which only launched in September, ran out of funds and released its entire 85-employee staff in mid-October, effectively shuttering the business.
Driver CEO and cofounder Dr....
